DermTech, Inc.
DMTK · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | -0.18 | 0.44 |
| FCF Yield | -136.34% | -185.38% | -14.20% | -5.54% |
| EV / EBITDA | -0.76 | -0.28 | -3.83 | -15.14 |
| Quality | ||||
| ROIC | -92.98% | -61.20% | -32.00% | -53.95% |
| Gross Margin | 1.80% | 4.46% | 10.76% | -1.63% |
| Cash Conversion Ratio | 0.76 | 0.82 | 0.79 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.92% | 35.12% | 52.10% | – |
| Free Cash Flow Growth | 20.99% | -52.05% | -112.42% | -69.54% |
| Safety | ||||
| Net Debt / EBITDA | -0.18 | 0.20 | 2.25 | 0.69 |
| Interest Coverage | 0.00 | -88.12 | 0.00 | -882.23 |
| Efficiency | ||||
| Inventory Turnover | 14.96 | 7.89 | 22.01 | 57.51 |
| Cash Conversion Cycle | 50.00 | 87.47 | 35.69 | 2.14 |